COMBINATION OF A PD-1 ANTAGONIST AND A LISTERIA BASED VACCINE FOR TREATING PANCREATIC CANCER

摘要

The present invention relates to combination therapies useful for the treatment of cancer. In particular, the invention relates to the treatment of pancreatic cancer using an antagonist of a Programmed Death 1 protein (PD-1) in combination with a live attenuated recombinant Listeria strain comprising a fusion protein of a PEST sequence-containing polypeptide fused to a tumor-associated antigen.